Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Emergent BioSolutions stock

EBS
US29089Q1058
A0LC2W

Price

9.19
Today +/-
+0.65
Today %
+8.15 %
P

Emergent BioSolutions stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Emergent BioSolutions stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Emergent BioSolutions stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Emergent BioSolutions stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Emergent BioSolutions's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Emergent BioSolutions Stock Price History

DateEmergent BioSolutions Price
10/2/20249.19 undefined
10/1/20248.47 undefined
9/30/20248.35 undefined
9/27/20247.49 undefined
9/26/20247.28 undefined
9/25/20245.94 undefined
9/24/20246.11 undefined
9/23/20246.06 undefined
9/20/20246.55 undefined
9/19/20246.99 undefined
9/18/20246.90 undefined
9/17/20246.88 undefined
9/16/20247.25 undefined
9/13/20247.87 undefined
9/12/20247.63 undefined
9/11/20247.57 undefined
9/10/20247.77 undefined
9/9/20247.68 undefined
9/6/20247.52 undefined
9/5/20247.63 undefined
9/4/20247.39 undefined

Emergent BioSolutions Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Emergent BioSolutions, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Emergent BioSolutions from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Emergent BioSolutions’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Emergent BioSolutions. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Emergent BioSolutions’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Emergent BioSolutions’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Emergent BioSolutions’s growth potential.

Emergent BioSolutions Revenue, EBIT and net profit per share

DateEmergent BioSolutions RevenueEmergent BioSolutions EBITEmergent BioSolutions Net Income
2029e999.9 M undefined0 undefined0 undefined
2028e789.62 M undefined11.21 M undefined-2.18 M undefined
2027e761.34 M undefined12.63 M undefined-2.18 M undefined
2026e1.15 B undefined-95.95 M undefined-66.56 M undefined
2025e1.15 B undefined-70.7 M undefined-62.74 M undefined
2024e1.12 B undefined-35.65 M undefined-111.3 M undefined
20231.05 B undefined-201.5 M undefined-760.5 M undefined
20221.12 B undefined-163.3 M undefined-211.6 M undefined
20211.77 B undefined383.1 M undefined219.5 M undefined
20201.56 B undefined480.1 M undefined305.1 M undefined
20191.11 B undefined114.1 M undefined54.5 M undefined
2018782.4 M undefined89.8 M undefined62.7 M undefined
2017560.9 M undefined124.3 M undefined82.6 M undefined
2016488.8 M undefined105.5 M undefined51.8 M undefined
2015489.3 M undefined141.5 M undefined62.9 M undefined
2014404.5 M undefined89.2 M undefined36.7 M undefined
2013312.7 M undefined45.6 M undefined31.1 M undefined
2012281.9 M undefined39.6 M undefined23.5 M undefined
2011273.4 M undefined34.6 M undefined23 M undefined
2010286.2 M undefined76.9 M undefined51.7 M undefined
2009234.8 M undefined40.2 M undefined31.1 M undefined
2008178.6 M undefined29.9 M undefined20.7 M undefined
2007182.9 M undefined33.1 M undefined22.9 M undefined
2006152.7 M undefined38.5 M undefined22.8 M undefined
2005130.7 M undefined37.9 M undefined15.8 M undefined
200483.5 M undefined13 M undefined11.5 M undefined

Emergent BioSolutions Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0.060.080.130.150.180.180.230.290.270.280.310.40.490.490.560.781.111.561.771.121.051.121.151.150.760.791
-50.9156.6316.9219.74-2.2031.4622.22-4.552.9311.0329.4921.04-0.2014.7539.6441.4340.6014.02-37.00-6.096.772.500.52-34.063.6826.62
60.0063.8676.1584.2178.0280.9080.3483.5784.6283.6380.1374.7577.9173.1665.1858.8260.7667.4057.8137.9632.70------
0.030.050.10.130.140.140.190.240.230.240.250.30.380.360.370.460.671.051.030.420.34000000
7133738332940763439458914110512489114480383-163-201-35-70-9512110
12.7315.6628.4625.0018.1316.2917.0926.5712.4513.8814.4222.0328.8321.5222.1411.3810.3130.8721.60-14.59-19.16-3.13-6.10-8.231.581.39-
411152222203151232331366251826254305219-211-760-111-62-66-2-20
-175.0036.3646.67--9.0955.0064.52-54.90-34.7816.1372.22-17.7460.78-24.39-12.90464.81-28.20-196.35260.19-85.39-44.146.45-96.97--
27.420.422.824.629.730.531.432.536.236.436.745.847.349.350.351.452.453.854.150.151.2000000
---------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Emergent BioSolutions Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Emergent BioSolutions is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (B)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
20042005200620072008200920102011201220132014201520162017201820192020202120222023
                                       
6.836.376.4105.791.5102.9171145.9141.7179.3280.5308.3271.5178.3112.2167.8621.3576.1642.6111.7
18.62.543.318.824.954.939.374.29660.658.8113.9138.5143.7262.5270.7272274.7159.2191
00.80.901012.58.89.505.61.46.6102.48.64.60000
13.316.424.716.918.313.512.714.715.214.665.760.974142.8205.8222.5307350.8350.7328.9
1.83.122.98.29.911.710.310.512.925.847.816.218.231.720.6-4.470.557.947.9
0.040.060.150.140.150.190.240.250.260.270.430.540.510.490.620.691.21.271.210.68
27.330.678.2110.2124.7131.8152.7209241.8264.2314327.8376.4407.2510.2567675.1828.4837399
00000000000000000000
00000000000000000000
00000051.451.441.871.911941.533.9119.6811.6741.9663.1604.6728.8566.6
00000055.55.51452.6414149.1259.7266.6266.7224.9218.20
1.310.612.71913.21947.726.611.83.42189.88.68.927.165.682.429171.9178.1
0.030.040.090.130.140.150.260.290.30.350.510.50.460.581.611.641.691.691.961.14
0.070.10.240.270.290.340.50.550.560.630.941.040.971.072.232.332.882.963.171.82
                                       
100000000000000100100100100100100100
7.634.690.9101.9109.2120.5197.7220.7231247.6274.2318352.4618.4688.6716.1784.9829.4873.5904.4
15.325.44870.391122.2173.9196.9220.4251.5288.3351.1254.5337.1367.3421.8726.9957.8738.7-21.8
0-0.3-0.5-1.1-0.9-1.5-2.1-3.3-4.1-3.5-3-2.7-4.3-3.7-5.5-9.9-25.3-16.13.1-5.7
00000000000000000000
0.020.060.140.170.20.240.370.410.450.50.560.670.60.951.051.131.491.771.620.88
5.510.427.420.318.317.225.440.531.327.540.93834.641.880.794.8136.1128.9103.5112.2
5.68.810.411.312.816.525.322.124.325.937.938.240.942.788.9105.5136.9146.212896.2
229.515.18.81.70.37.83.11.83.314.123.410.315.620.73.177.767.140.129.2
008.911.81515000000200000000
11.42.53.56.25.817.25.44.50000010.112.933.831.6957.3413.7
0.030.030.060.060.050.050.080.070.060.060.090.10.110.10.20.220.380.371.230.65
11.810.531.442.635.944.930.254.158.362251246.9248.113.5784.5798.4841809.4448.5446.5
0000000001.4000067.563.953.294.959.747.2
0.104.14.11.51.220.851.917.441.6312044.3166.1160.2157.561.941.528.9
0.010.010.040.050.040.050.050.060.060.080.290.280.270.061.021.021.050.970.550.52
0.050.040.10.10.090.10.130.130.120.140.390.380.370.161.221.241.441.341.781.17
0.070.10.240.270.290.340.50.540.570.630.951.040.981.112.272.372.923.113.392.05
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Emergent BioSolutions provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Emergent BioSolutions's financial health and stability.

Assets

Emergent BioSolutions's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Emergent BioSolutions must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Emergent BioSolutions after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Emergent BioSolutions's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200320042005200620072008200920102011201220132014201520162017201820192020202120222023
411152222202647161830366251826254305230-223-760
11344556911193235384262110114123143125
00-111525920313163538-1-246-19-8
3-47-3325-21-2523-46-122413-65-4553-119-428-156-30-75
20260-342220233021262422415093161118110536
000133121223788103421303368
40182141615224664281012143010971652
11942-45572998123997112445320841188536321-34-206
-4-17-6-41-44-20-33-22-54-53-42-30-44-76-54-72-96-151-225-359-57
-7-18-7-41-44-30-33-23-54-40-67-210-45-76-249-897-96-151-225-381212
-3-1000-100-1013-25-17900-195-825000-21270
000000000000000000000
011-1301508-18123018020-207951362-35564-543
00054234710-56132517-1315831-90-7710
08-58518914-916-1819833-18-51788-3569-141481-535
0-2-400611-50245-35-17-22-57-25-15-5-2
000000000000000000000
20294029-141166-25-23710132-41-93-6655453-4566-530
7-7.935.8-45.311.4-13.5-3.476.8-41.8-14.25581.6-0.3-22.8153.3-30.391.138596.1-393.6-264.2
000000000000000000000

Emergent BioSolutions stock margins

The Emergent BioSolutions margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Emergent BioSolutions. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Emergent BioSolutions.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Emergent BioSolutions's sales revenue. A higher gross margin percentage indicates that the Emergent BioSolutions retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Emergent BioSolutions's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Emergent BioSolutions's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Emergent BioSolutions's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Emergent BioSolutions. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Emergent BioSolutions's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Emergent BioSolutions Margin History

Emergent BioSolutions Gross marginEmergent BioSolutions Profit marginEmergent BioSolutions EBIT marginEmergent BioSolutions Profit margin
2029e32.77 %0 %0 %
2028e32.77 %1.42 %-0.28 %
2027e32.77 %1.66 %-0.29 %
2026e32.77 %-8.31 %-5.77 %
2025e32.77 %-6.15 %-5.46 %
2024e32.77 %-3.18 %-9.93 %
202332.77 %-19.2 %-72.48 %
202237.98 %-14.61 %-18.94 %
202157.82 %21.6 %12.38 %
202067.42 %30.87 %19.62 %
201960.8 %10.32 %4.93 %
201858.81 %11.48 %8.01 %
201765.11 %22.16 %14.73 %
201673.14 %21.58 %10.6 %
201578.03 %28.92 %12.86 %
201474.78 %22.05 %9.07 %
201380.14 %14.58 %9.95 %
201283.65 %14.05 %8.34 %
201184.56 %12.66 %8.41 %
201083.54 %26.87 %18.06 %
200980.28 %17.12 %13.25 %
200880.91 %16.74 %11.59 %
200777.97 %18.1 %12.52 %
200684.22 %25.21 %14.93 %
200575.82 %29 %12.09 %
200463.95 %15.57 %13.77 %

Emergent BioSolutions Stock Sales Revenue, EBIT, Earnings per Share

The Emergent BioSolutions earnings per share therefore indicates how much revenue Emergent BioSolutions has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Emergent BioSolutions earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Emergent BioSolutions's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Emergent BioSolutions’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Emergent BioSolutions's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Emergent BioSolutions Revenue, EBIT and net profit per share

DateEmergent BioSolutions Sales per ShareEmergent BioSolutions EBIT per shareEmergent BioSolutions Earnings per Share
2029e18.51 undefined0 undefined0 undefined
2028e14.62 undefined0 undefined-0.04 undefined
2027e14.09 undefined0 undefined-0.04 undefined
2026e21.36 undefined0 undefined-1.23 undefined
2025e21.27 undefined0 undefined-1.16 undefined
2024e20.75 undefined0 undefined-2.06 undefined
202320.49 undefined-3.94 undefined-14.85 undefined
202222.31 undefined-3.26 undefined-4.22 undefined
202132.78 undefined7.08 undefined4.06 undefined
202028.91 undefined8.92 undefined5.67 undefined
201921.11 undefined2.18 undefined1.04 undefined
201815.22 undefined1.75 undefined1.22 undefined
201711.15 undefined2.47 undefined1.64 undefined
20169.91 undefined2.14 undefined1.05 undefined
201510.34 undefined2.99 undefined1.33 undefined
20148.83 undefined1.95 undefined0.8 undefined
20138.52 undefined1.24 undefined0.85 undefined
20127.74 undefined1.09 undefined0.65 undefined
20117.55 undefined0.96 undefined0.64 undefined
20108.81 undefined2.37 undefined1.59 undefined
20097.48 undefined1.28 undefined0.99 undefined
20085.86 undefined0.98 undefined0.68 undefined
20076.16 undefined1.11 undefined0.77 undefined
20066.21 undefined1.57 undefined0.93 undefined
20055.73 undefined1.66 undefined0.69 undefined
20044.09 undefined0.64 undefined0.56 undefined

Emergent BioSolutions business model

Emergent BioSolutions Inc is a biotechnology company specializing in the development of products for protection against biological threats, infectious diseases, and cancer. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland, USA. Emergent BioSolutions' business model is based on developing and marketing innovative products for the protection of public health and national security. The company aims to respond to known and unknown threats and focus on the changing healthcare needs of society. Emergent BioSolutions operates in four business segments: Biosavérica, Vaccines, Therapeutics, and Contract Manufacturing. Biosavérica is a Latin American subsidiary specializing in the distribution of biological products in Central and South America. Vaccines develops and produces vaccines for infectious diseases such as anthrax, cholera, and typhoid. Therapeutics focuses on the development of anti-infectives and cancer therapeutics. Contract Manufacturing offers services to the biopharmaceutical industry, including the manufacturing, development, and analysis of biopharmaceutical products. Emergent BioSolutions' products include vaccines, antitoxins, antibodies, and therapeutics. One of their most well-known products is BioThrax, an anthrax vaccine used by the US government for defense against biological threats since 2002. Other products include the cholera vaccine Vaxchora, the flu medication FluBlok, and the antibody Anthim used for anthrax. Emergent BioSolutions has partnerships with various governments and organizations worldwide, including the US government, the European Commission, and the World Health Organization. This collaboration aims to ensure that Emergent BioSolutions provides products and services in the areas of national security and public health and enables a rapid response in the event of epidemics and pandemics. In recent years, Emergent BioSolutions has also made several acquisitions to strengthen its business. In 2017, they acquired Cangene Corporation, a company specialized in the manufacture of anti-infectives and antitoxins. In 2019, Emergent BioSolutions acquired PaxVax, a company developing vaccines for infectious diseases, and Adapt Pharma, a company specializing in antidotes for opioid overdose. Emergent BioSolutions is a company focused on innovative research and development, offering products for the protection of public health and national security. The company has experienced significant growth in recent years and strives to adapt to the changing healthcare needs of society. Emergent BioSolutions is one of the most popular companies on Eulerpool.com.

Emergent BioSolutions Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Emergent BioSolutions Revenue by Segment

Segmente2015
Contract development and manufacturing services-
Contracts and grants-
Product sales, net-
Products-
CDMO services-
Contract development and manufacturing services-
Revenue earned during the period arising from manufacturing sale under the terms of a contract-
Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and grants-
Product Sales-
Segment of the Company which develops vaccines, antibody therapies and technology platforms for use against infectious diseases, oncology, autoimmune and inflammatory disorders and other medical conditions that have resulted in significant unmet or underserved public health needs72.7 M USD
Segment of the Company which develops, manufactures and commercializes vaccines and antibody therapies for use against biological agents that are potential weapons of bioterrorism or biowarfare-1.88 M USD
All Other-

Emergent BioSolutions Revenue by Region

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Emergent BioSolutions Revenue by Segment

DateCanadaNon-U.S. GovernmentOther CountriesU.S GovernmentU.S. GovernmentUnited States
2022148.6 M USD-82.8 M USD--889.5 M USD
2021-894.9 M USD-897.8 M USD--
2020-566.9 M USD-988.5 M USD--
2019--431.3 M USD--674.7 M USD
2018-80.4 M USD--597.6 M USD-

Emergent BioSolutions SWOT Analysis

Strengths

Emergent BioSolutions Inc has several strengths that contribute to their success:

  • Strong reputation in the biopharmaceutical industry
  • Extensive experience and expertise in biodefense and public health
  • Diverse portfolio of products and services
  • Strategic partnerships with government agencies and international organizations
  • Robust research and development capabilities

Despite its strengths, Emergent BioSolutions Inc also faces certain weaknesses:

  • Dependency on government contracts, which may be subject to political changes
  • Relatively high research and development expenses

Emergent BioSolutions Inc can leverage the following opportunities to further grow its business:

  • Increasing global demand for biodefense and public health solutions
  • New product developments and innovations
  • Expansion into emerging markets
  • Potential collaborations with other biopharmaceutical companies

Emergent BioSolutions Inc faces certain threats that could impact its operations:

  • Intense competition in the biopharmaceutical industry
  • Uncertainty in government funding for biodefense and public health initiatives
  • Regulatory challenges and compliance requirements
  • Risks associated with product recalls or safety concerns

Weaknesses

Despite its strengths, Emergent BioSolutions Inc also faces certain weaknesses:

  • Dependency on government contracts, which may be subject to political changes
  • Relatively high research and development expenses

Emergent BioSolutions Inc can leverage the following opportunities to further grow its business:

  • Increasing global demand for biodefense and public health solutions
  • New product developments and innovations
  • Expansion into emerging markets
  • Potential collaborations with other biopharmaceutical companies

Emergent BioSolutions Inc faces certain threats that could impact its operations:

  • Intense competition in the biopharmaceutical industry
  • Uncertainty in government funding for biodefense and public health initiatives
  • Regulatory challenges and compliance requirements
  • Risks associated with product recalls or safety concerns

Opportunities

Emergent BioSolutions Inc can leverage the following opportunities to further grow its business:

  • Increasing global demand for biodefense and public health solutions
  • New product developments and innovations
  • Expansion into emerging markets
  • Potential collaborations with other biopharmaceutical companies

Emergent BioSolutions Inc faces certain threats that could impact its operations:

  • Intense competition in the biopharmaceutical industry
  • Uncertainty in government funding for biodefense and public health initiatives
  • Regulatory challenges and compliance requirements
  • Risks associated with product recalls or safety concerns

Threats

Emergent BioSolutions Inc faces certain threats that could impact its operations:

  • Intense competition in the biopharmaceutical industry
  • Uncertainty in government funding for biodefense and public health initiatives
  • Regulatory challenges and compliance requirements
  • Risks associated with product recalls or safety concerns

Emergent BioSolutions Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Emergent BioSolutions historical P/E ratio, EBIT multiple, and P/S ratio

Emergent BioSolutions shares outstanding

The number of shares was Emergent BioSolutions in 2023 — This indicates how many shares 51.2 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Emergent BioSolutions earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Emergent BioSolutions's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Emergent BioSolutions’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Emergent BioSolutions's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Emergent BioSolutions.

Emergent BioSolutions latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.95 -2.32  (-143.06 %)2024 Q2
3/31/2024-0.87 0.59  (167.93 %)2024 Q1
12/31/2023-0.19 -0.77  (-301.25 %)2023 Q4
9/30/2023-0.23 -0.48  (-112.77 %)2023 Q3
6/30/2023-0.49 -1.06  (-115.67 %)2023 Q2
3/31/2023-1.25 -3.17  (-153.11 %)2023 Q1
12/31/20220.04 -0.31  (-798.2 %)2022 Q4
9/30/2022-0.06 -1.27  (-1,938.52 %)2022 Q3
6/30/20220.38 -0.86  (-327.03 %)2022 Q2
3/31/20220.13 0.18  (42.52 %)2022 Q1
1
2
3
4
5
...
8

Eulerpool ESG Scorecard© for the Emergent BioSolutions stock

Eulerpool World ESG Rating (EESG©)

51/ 100

🌱 Environment

41

👫 Social

77

🏛️ Governance

36

Environment

Scope 1 - Direct Emissions
19,334
Scope 2 - Indirect emissions from purchased energy
21,099
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
40,434
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees48.3
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management12.8
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share4.3
Percentage of Black employees—
Black Management Share11.2
Percentage of white employees—
White Management Share68.2
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Emergent BioSolutions shareholders

%
Name
Stocks
Change
Date
5.50655 % The Vanguard Group, Inc.2,974,638336,24512/31/2023
5.32022 % Charles Schwab Investment Management, Inc.2,873,9841,312,93412/31/2023
4.98810 % BlackRock Financial Management, Inc.2,694,572437,34012/31/2023
3.93613 % Two Sigma Investments, LP2,126,30023,02412/31/2023
3.87942 % Millennium Management LLC2,095,662-1,570,71712/31/2023
3.04932 % Hotchkis and Wiley Capital Management, LLC1,647,243-781,24712/31/2023
2.19650 % D. E. Shaw & Co., L.P.1,186,552250,03412/31/2023
2.04607 % Jacobs Levy Equity Management, Inc.1,105,285-203,92612/31/2023
2.03113 % Geode Capital Management, L.L.C.1,097,21978,18412/31/2023
2.01914 % Morgan Stanley & Co. LLC1,090,738569,84212/31/2023
1
2
3
4
5
...
10

Emergent BioSolutions Executives and Management Board

Mr. Richard Lindahl59
Emergent BioSolutions Chief Financial Officer, Executive Vice President, Treasurer
Compensation 3.52 M
Ms. Jennifer Fox50
Emergent BioSolutions Executive Vice President - External Affairs, General Counsel, Corporate Secretary
Compensation 2.92 M
Dr. Zsolt Harsanyi79
Emergent BioSolutions Independent Chairman of the Board
Compensation 512,500
Mr. Keith Katkin51
Emergent BioSolutions Independent Director
Compensation 446,250
Dr. Adm. Kathryn Zoon74
Emergent BioSolutions Independent Director
Compensation 427,500
1
2
3

Emergent BioSolutions Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Soligenix Stock
Soligenix
SupplierCustomer0,910,860,930,630,780,87
Indivior Stock
Indivior
SupplierCustomer0,880,73-0,20-0,63-0,87-0,84
Humanigen Stock
Humanigen
SupplierCustomer0,760,560,750,350,860,68
Merck & Co Stock
Merck & Co
SupplierCustomer0,730,02-0,68-0,62-0,55-0,38
ChemoMetec Stock
ChemoMetec
SupplierCustomer0,720,640,68-0,060,40-0,76
AstraZeneca Stock
AstraZeneca
SupplierCustomer0,610,69-0,35-0,67-0,63-0,56
Vaxart Stock
Vaxart
SupplierCustomer0,590,680,920,730,840,44
Opiant Pharmaceuticals Stock
Opiant Pharmaceuticals
SupplierCustomer0,200,420,720,71-0,40-0,76
GlaxoSmithKline Stock
GlaxoSmithKline
SupplierCustomer0,160,44-0,53-0,52-0,77-0,49
Aridis Pharmaceuticals Stock
Aridis Pharmaceuticals
SupplierCustomer0,010,470,870,630,830,85
1
2

Most common questions regarding Emergent BioSolutions

What values and corporate philosophy does Emergent BioSolutions represent?

Emergent BioSolutions Inc represents values of integrity, innovation, and dedication to public health. Following their corporate philosophy, they strive to deliver high-quality products and solutions for public health threats. The company focuses on developing, manufacturing, and delivering medical countermeasures for biodefense and emerging infectious diseases. By collaborating with governments, healthcare organizations, and stakeholders worldwide, Emergent BioSolutions Inc aims to protect and enhance the well-being of individuals and communities. With a commitment to scientific expertise and a patient-centered approach, they contribute to the preparedness and response efforts in the face of various health challenges.

In which countries and regions is Emergent BioSolutions primarily present?

Emergent BioSolutions Inc primarily operates in the United States. As a global specialty biopharmaceutical company, the company's headquarters are located in Gaithersburg, Maryland. With a strong presence in the United States, Emergent BioSolutions Inc focuses on developing and manufacturing therapies for public health threats. The company's products are used in various countries and regions worldwide, supporting preparedness and response efforts for biodefense, emerging infectious diseases, and other public health emergencies.

What significant milestones has the company Emergent BioSolutions achieved?

Emergent BioSolutions Inc, a leading biopharmaceutical company, has achieved significant milestones in its journey. Notably, the company received a U.S. FDA licensure for its proprietary BioThrax® vaccine against anthrax, establishing itself as the sole provider of such a critical defense product for the U.S. government. Additionally, Emergent successfully developed and commercialized various medical countermeasures, including Vaccinia Immune Globulin Intravenous (VIGIV) for smallpox treatment and Trobigard® auto-injector for atropine/pralidoxime chloride poisoning. Furthermore, the company obtained FDA approval for its first-in-class narcolepsy therapy, NARCAN® nasal spray. These achievements highlight Emergent BioSolutions Inc's commitment to enhancing public health through innovative solutions and its contributions to epidemic and pandemic preparedness.

What is the history and background of the company Emergent BioSolutions?

Emergent BioSolutions Inc is a renowned pharmaceutical company with a rich history and background. Established in 1998, Emergent is dedicated to developing innovative solutions to address public health threats. Over the years, the company has built a strong reputation for its expertise in biodefense, vaccines, therapeutics, and contract manufacturing services. Emergent BioSolutions has played a crucial role in supplying vaccines and treatments for various diseases, including anthrax, smallpox, and COVID-19. With a commitment to protecting and enhancing global health, Emergent continues to be at the forefront of life-saving medical advancements.

Who are the main competitors of Emergent BioSolutions in the market?

Emergent BioSolutions Inc faces competition from several players in the market. Some of the main competitors of Emergent BioSolutions Inc include companies like Pfizer Inc, GlaxoSmithKline plc, Sanofi SA, and Johnson & Johnson. These companies are also involved in the biopharmaceutical sector and operate in similar areas such as vaccine development, contract manufacturing, and biodefense solutions. However, Emergent BioSolutions Inc has positioned itself as a leader in the industry, particularly due to its expertise in biodefense solutions and its strong portfolio of products and services.

In which industries is Emergent BioSolutions primarily active?

Emergent BioSolutions Inc is primarily active in the biopharmaceutical industry.

What is the business model of Emergent BioSolutions?

The business model of Emergent BioSolutions Inc revolves around being a global specialty biopharmaceutical company. With a focus on developing and manufacturing vaccines and therapeutics, Emergent BioSolutions Inc aims to address public health threats. The company operates through three segments: Vaccines and Anti-Infectives, Contract Development and Manufacturing Organization (CDMO), and Devices. Through partnerships, strategic acquisitions, and government contracts, Emergent BioSolutions Inc has built a strong portfolio of products and capabilities to provide solutions in areas such as infectious diseases, opioid overdose, and weapons of mass destruction.

What is the P/E ratio of Emergent BioSolutions 2024?

The Emergent BioSolutions P/E ratio is -4.23.

What is the P/S ratio of Emergent BioSolutions 2024?

The Emergent BioSolutions P/S ratio is 0.42.

What is the AlleAktien quality score of Emergent BioSolutions?

The AlleAktien quality score for Emergent BioSolutions is 2/10.

What is the revenue of Emergent BioSolutions 2024?

The expected Emergent BioSolutions revenue is 1.12 B USD.

How high is the profit of Emergent BioSolutions 2024?

The expected Emergent BioSolutions profit is -111.3 M USD.

What is the business model of Emergent BioSolutions

Emergent BioSolutions Inc. is a US biotechnology company based in Gaithersburg, Maryland. They specialize in the development and manufacturing of biological products, including vaccines and antibodies, to combat infectious diseases, as well as medications and products for emergency situations. The company is divided into three business segments: BioDefense, Civilian Emergency Medicine, and Emergent Family of Companies. Each segment focuses on a specific market and has its own products. The BioDefense segment develops and produces vaccines and antibodies used to combat bioterrorist threats such as anthrax, smallpox, and botulism. This includes the BioThrax vaccine, the only FDA-approved anthrax vaccine in the US, as well as anthrax countermeasures such as Anthrasil. In Civilian Emergency Medicine, Emergent offers products for the treatment of acute medical emergencies, including medical devices and diagnostic equipment for rapid testing. In this segment, Emergent also has several partnerships with government agencies and health organizations to provide products needed in natural disasters and other emergencies. The Emergent Family of Companies includes Emergent's acquisitions and partnerships in other areas and niches of biotechnology, including medical device manufacturing and the development of therapies for various indications such as cancer, autoimmune diseases, and infectious diseases. An important focus of Emergent is collaboration with government agencies and international partners. The company has a specialized team that works with various government organizations and institutions in the US and around the world. This gives Emergent access to specialized resources and enables them to develop and produce products that meet the requirements of the respective government agencies and organizations. As a company with a strong focus on research and development, Emergent invests significant amounts in expanding its product pipeline. Future products include vaccines and therapies for HIV, Ebola, and Zika. Emergent primarily markets its products to government agencies and health organizations. However, the company also benefits from the increasing demand for products to combat infectious diseases due to natural disasters or bioterrorist attacks. Overall, Emergent BioSolutions is a key player in the medical and biotech industry, especially in terms of the development and production of biologics. The company's threefold division allows it to operate in various biotechnology niches and constantly expand its product pipeline. Collaboration with government agencies and the ability to quickly respond to changing requirements are crucial factors for the success of Emergent BioSolutions.

What is the Emergent BioSolutions dividend?

Emergent BioSolutions pays a dividend of 0 USD distributed over payouts per year.

How often does Emergent BioSolutions pay dividends?

The dividend cannot currently be calculated for Emergent BioSolutions or the company does not pay out a dividend.

What is the Emergent BioSolutions ISIN?

The ISIN of Emergent BioSolutions is US29089Q1058.

What is the Emergent BioSolutions WKN?

The WKN of Emergent BioSolutions is A0LC2W.

What is the Emergent BioSolutions ticker?

The ticker of Emergent BioSolutions is EBS.

How much dividend does Emergent BioSolutions pay?

Over the past 12 months, Emergent BioSolutions paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Emergent BioSolutions is expected to pay a dividend of 0 USD.

What is the dividend yield of Emergent BioSolutions?

The current dividend yield of Emergent BioSolutions is .

When does Emergent BioSolutions pay dividends?

Emergent BioSolutions pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Emergent BioSolutions?

Emergent BioSolutions paid dividends every year for the past 0 years.

What is the dividend of Emergent BioSolutions?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Emergent BioSolutions located?

Emergent BioSolutions is assigned to the 'Health' sector.

Wann musste ich die Aktien von Emergent BioSolutions kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Emergent BioSolutions from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.

When did Emergent BioSolutions pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of Emergent BioSolutions in the year 2023?

In the year 2023, Emergent BioSolutions distributed 0 USD as dividends.

In which currency does Emergent BioSolutions pay out the dividend?

The dividends of Emergent BioSolutions are distributed in USD.

All fundamentals about Emergent BioSolutions

Our stock analysis for Emergent BioSolutions Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Emergent BioSolutions Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.